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Abstract
Background: Ginseng is believed to have beneficial effects against human diseases, and its active
components, ginsenosides, may play critical roles in its diverse physiological actions. However, the
mechanisms underlying ginseng's effects remain to be investigated. We hypothesize some biological
effects of ginseng are due to its anti-inflammatory effects.
Methods: Human promonocytic U937 cells were used to investigate the immunomodulatory
effects of ginseng following TNF-α treatment. A global gene expression profile was obtained by
using genechip analysis, and specific cytokine expression was measured by quantitative RT-PCR and
ELISA. HPLC was used to define the composition of ginsenosides in 70% ethanol-water extracts of
ginseng. Activation of signalling kinases was examined by Western blot analysis.
Results: Seventy percent ethanol-water extracts of ginseng significantly inhibited the transcription
and secretion of CXCL-10 following TNF-α stimulation. Nine ginsenosides including Rb1, Rb2, Rc,
Rd, Re, Rf, Rg1, Rg3 and Rh1 were identified in our extract by HPLC. Seven out of nine ginsenosides
could significantly inhibit TNF-α-induced CXCL-10 expression in U937 cells and give comparable
inhibition of CXCL-10 transcription to those with the extract. However, the CXCL-10 suppressive
effect of individual ginsenosides was less than that of the crude extract or the mixture of
ginsenosides. The CXCL-10 suppression can be correlated with the inactivation of ERK1/2
pathways by ginseng.
Conclusion: We showed ginseng suppressed part of the TNF-α-inducible cytokines and signalling
proteins in promonocytic cells, suggesting that it exerts its anti-inflammatory property targeting at
different levels of TNF-α activity. The anti-inflammatory role of ginseng may be due to the
combined effects of ginsenosides, contributing in part to the diverse actions of ginseng in humans.
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Background
Panax ginseng (ginseng) has been used as a herbal remedy
in ancient China and Asian countries for thousands of
years and became popular in Western countries during the
last two decades [1]. Ginseng roots contain multiple
active constituents including ginsenosides, polysaccha-
rides, peptides, polyacetylenic alcohols and fatty acids
that have been shown to have different effects on carbohy-
drate and lipid metabolism as well as on the function of
neuroendocrine, immune, cardiovascular and central
nervous systems in humans [1,2]. Previous studies have
shown that ginseng and its active components are potent
immunomodulators. Their immunomodulatory effects
are mostly due to its regulation of cytokine production
and phagocytic activities of monocytes/macrophages and
dendritic cells, as well as activation of T- and B- lym-
phocytes [3-8].
In addition, ginseng has been shown to have potent regu-
latory effects on the inflammatory cascade. Ginsan, a
polysaccharide extract from ginseng, enhances the phago-
cytic activity of macrophages in mice infected with Staphy-
lococcus aureus [9]. Ginsan also inhibits the production of
proinflammatory cytokines including tumour necrosis
factor-α (TNF-α), interleukin-1β (IL-1β), IL-6, IL-12, IL-18
and interferon-γ (IFN-γ) by suppressing the activity of
mitogen activated protein kinases (MAPK) including p38
MAPK and JNK, and the transcription factor nuclear fac-
tor-kappaB (NF-κB). The ginseng root extract stimulates
the inducible nitric oxide synthase (iNOS) activity in
RAW264.7 murine macrophages [10].
Ginsenosides, the steroid saponins, are major biologically
active compounds of ginseng. Over 30 ginsenosides have
been identified to date [11]. Studies indicate that ginseno-
sides and their metabolites are responsible for many of
the diverse physiological actions including the anti-
inflammatory effects of ginseng. For example, ginsenoside
Rh1 reduces histamine release from rat peritoneal mast
cells and the IgE-mediated passive cutaneous anaphylaxis
reaction in mice [12]. Rh1 and 20(S)-Protopanaxatriol
inhibit the LPS-induced expression of iNOS and cycloox-
ygenase-2 (COX-2) in RAW264.7 cells through the inacti-
vation of NF-κB [12,13]. Ginsenoside Rg3 inhibits the
expression of 12-O-tetradecanoylphorbol-13-acetate-
induced COX-2 as well as activation of NF-κB and AP-1 in
mouse skin and human pro-myelocytic leukemia cells
[14].
Proinflammatory cytokine TNF-α has been shown to play
a central role in the pathogenesis of both acute infectious
diseases and chronic inflammatory conditions [15,16].
Production of TNF-α by the host is one of the important
defence mechanisms against bacterial, viral or parasitic
infections. However, excess local TNF-α production can
promote the neighbouring tissue damage and inflamma-
tion through the induction of chemokines and other fac-
tors [15]. Hence, different anti-TNF-α therapies have been
developed for patients with chronic inflammatory dis-
eases including rheumatoid arthritis, Crohn's disease and
psoriasis [15,17].
To investigate the immunomodulatory effects of Panax
ginseng, genechip analysis was used to examine the gene
expression profile of TNF-α-treated human monocytic
U937 cells with or without pre-treatment with a Panax gin-
seng extract (PGSE). The semi-quantitative results on spe-
cific cytokines were validated by quantitative RT-PCR and
ELISA. Moreover, the composition of ginsenosides in the
PGSE was determined by using high performance liquid
chromatography (HPLC) analysis. The effects of individ-
ual ginsenoside or mixtures of HPLC-defined ginseno-
sides on U937 cells with subsequent TNF-α treatment
were examined by quantitative RT-PCR analysis. Our
results may contribute to the understanding of the molec-
ular mechanisms of the immunomodulatory effect of gin-
seng and ginsenosides on TNF-α-mediated inflammatory
diseases.
Methods
Preparation of 70% ethanol-water extracts of ginseng 
(PGSE)
The  Panax ginseng extract was provided by Prof Wang
Jianxin (Shanghai Institute of Chinese Materia Medica,
PRChina). Briefly, the crude plant material of ginseng was
cut into slices of 1 to 3 mm, and then placed in a flask that
was heated with 70% ethanol-water under reflux for 6
hours. The experiment was repeated twice. The ratio of the
plant material to the menstruum was 1:10. The resultant
extract was concentrated by evaporation and then dried by
lyophilization to obtain PGSE at a yield between 20 to
25% (w/w, dried extract/crude herb). The extract was
grinded and then passed through an 80 mesh screen.
High performance liquid chromatography analysis of 
PGSE
Ginsenosides standards were purchased from Chroma-
dex. HPLC analysis on the composition of ginsenosides in
PGSE (2 mg in 1.5 ml of milli-Q water) was performed by
using an Agilent 1200 liquid chromatography system that
was equipped with a quaternary solvent delivery system,
an autosampler and photodiode array detector. A
reversed-phase column, Lichrospher C18 (250 mm × 4.6
mm i.d., 5 μm), was used for all separations. The gradient
program, modified from a previous report [18], consisted
of (A) water and (B) acetonitrile at a flow of 1 mL/min, as
follows: 0–6 min, 21–22% B; 6–7 min, 22–23% B; 7–25
min, 23–24% B; 25–30 min, 24–30% B; 30–40 min, 30–
32% B; 40–45 min, 32–50% B; 45–60 min, 50–65% B;
60–61 min, 65–100% B; and 61–65 min, back to 21% BJournal of Translational Medicine 2009, 7:34 http://www.translational-medicine.com/content/7/1/34
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before the next injection. The injection volume was 15 μl
and the UV detection wavelength was performed at 203
nm for all ginsenosides and PGSE.
Cell culture
The human promonocytic U937 cells [19] were obtained
from American Type Culture Collection (ATCC accession
no. CRL-1593.2™) and were cultured in RPMI 1640
medium (Invitrogen) supplemented with 10% foetal
bovine serum (Invitrogen), penicillin (100 U/ml) and
streptomycin (100 μg/ml) in a 5% CO2 incubator at 37°C.
Cells were incubated with TNF-α (20 units/ml) for 2
hours with or without the pre-treatment of PGSE for 24
hours and harvested for genechip analysis. The PGSE con-
centrations used in our report are based on previous stud-
ies of ginseng by other investigators [20,21] and verified
by our cytotoxicity tests. The effective doses of ginseno-
sides in other groups' in vitro studies ranged from 10 – 100
μM or 0.01 – 0.1 mg/ml. Similarly, the concentrations of
individual ginsenosides in 3 mg PGSE used in our experi-
ments ranged from 0.01 to 0.14 mg/ml (Table 1). There-
fore, at these low concentrations, it is conceivable that the
ginsenoside content of 3 mg/ml PGSE is achievable in
vivo. In addition, we determined the cytotoxic effects of
PGSE at 3 mg/ml by trypan blue exclusion assay. The via-
bility of cells was over 90% after incubating U937 cells
with the PGSE for 48 hours.
Cytotoxicity test of PGSE
Cytotoxic effects of PGSE on U937 cells were examined by
incubating 3 mg/ml of PGSE for 48 hours and the cell via-
bility was determined by using trypan blue exclusion test.
There is no significant sign of cytotoxicity found at 3 mg/
ml of PGSE.
Limulus amebocyte lysate test
The amount of bacterial endotoxin in PGSE was measured
by Pyrotell Limulus amebocyte lysate assay kit (Associates
of Cape Cod) according to the manufacturer's protocol.
Briefly, 0.2 ml of various concentrations of PGSE was
added to a single test vial of Pyrotell. The reaction mixture
was incubated at 37°C for 60 min and then inverted to
observe the gel formation. Positive result is indicated by
the formation of an intact gel which does not collapse
upon inversion. The levels of endotoxin in PGSE at 10
mg/ml were lower than the detection limit of the test
(<0.05 ng/ml) indicating that the biological effects of
PGSE are not due to endotoxin contamination.
Isolation of RNA and microarray analysis
U937 cells (1 × 106) were pretreated with or without 3
mg/ml PGSE for 24 hours followed by 20 units/ml TNF-α
for 2 hours and Genechip analysis was followed by using
Affymetrix's protocol. Briefly, total cellular RNA was
extracted using TRIzol (Invitrogen) and further purified
by RNeasy cleanup kit (Qiagen) according to the manu-
facturer's instructions. The RNA integrity was determined
by the ratio of 28S/18S ribosomal RNA using Agilent
2100 Bioanalzyer. For genechip analysis, total RNA (1 μg)
were reverse transcribed to the first-stranded cDNA by
using oligo (dT) linked-T7 RNA polymerase promoter
sequence and the double-stranded cDNA was synthesized
by using RT Kit (Invitrogen). The biotin labelled-cRNA
was generated by in vitro transcription kit (Invitrogen),
purified by RNeasy mini columns (Qiagen), denatured
and 15 μg cRNA was hybridized to Human Genome U133
Plus 2.0 arrays (Affymetrix). Then, the arrays were stained
with a streptavidin-phycoerythrin conjugate and visual-
ized with GeneArray scanner (Agilent). The genechip data
were analyzed by using Agilent Genespring GX and
Affymetrix GeneChip Operating Softwares (GCOS). The
signal intensity of each gene was firstly normalized with
the total intensity of all genes from the genechip, and then
the normalized signal of each treatment was compared
with the mock-treatment to determine the relative fold
changes of gene expression. The threshold level for up- or
down-regulation of gene expression was the level of
changes ≥2-fold.
Table 1: Distribution of ginsenosides in Panax ginseng extract.
GS Amount of GS in 3 mg of PGSE (mg) Molarity
(mM)
Percentage of GS in 3 mg of PGSE (w/w)
Rb1 0.14 0.13 4.7%
Rb2 0.07 0.06 2.5%
Rc 0.08 0.07 2.8%
Rd 0.04 0.04 1.3%
Re 0.07 0.07 2.2%
Rf 0.01 0.01 0.4%
Rg1 0.12 0.15 4.0%
Rg3 0.02 0.03 0.6%
Rh1 0.01 0.02 0.3%
Rh2 0.00 0.00 0.0%
Total: 18.8%
The amount of ginsenosides was determined using HPLC (n = 2); GS, ginsenosides; Panax ginseng extract, PGSE.Journal of Translational Medicine 2009, 7:34 http://www.translational-medicine.com/content/7/1/34
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Quantitative RT-PCR analysis
U937 cells were treated as described in genechip analysis
and the procedures of quantitative RT-PCR analysis were
described in our previous studies [22-24]. Briefly, DNase-
treated RNA samples were reverse transcribed using Taq-
Man reverse transcription reagent kit (Applied Biosys-
tems) and the levels of CXCL-10, IL-8 and TNFAIP3
mRNA as well as the reference gene 18S rRNA were
assayed by the gene-specific TaqMan gene expression
assays (Applied Biosystems). All samples and controls
were run in triplicates on an ABI 7500 Real-time PCR sys-
tem. The quantitative RT-PCR data was analyzed by the
comparative cycle number threshold method and the fold
inductions of samples were compared with the untreated
samples.
ELISA
U937 cells were pre-treated with or without PGSE (3 mg/
ml) for 24 hours prior to TNF-α (20 units/ml) stimulation
for 16 hours. After treatment, the levels of CXCL-10 and
IL-8 in culture supernatant were measured by using the
respective commercially available specific ELISA kits
(R&D Systems).
Preparation of protein lysate
U937 cells were pre-treated with or without PGSE (1 or 3
mg/ml) for 24 hours followed by TNF-α (20 units) stimu-
lation for 2 hours. To prepare the whole cell lysate, cells
were washed with PBS and lysed with ice-cold lysis buffer
containing 1% Triton X-100, 25 mM HEPES, 5 mM EDTA,
100 mM NaCl, 0.1 mg/ml PMSF, 2 μg/ml aprotinin, 1 mM
sodium orthovanadate, 2 μg/ml pepstatin, 2 μg/ml leu-
peptin, 50 mM sodium fluoride and 10 mM beta-glycero-
phosphate for 20 min on ice. The total protein was
harvested by centrifugation at 13000 rpm for 10 min at
4°C. The supernatants were stored as aliquots at -70°C.
Western analysis
Protein concentration was determined by BCA protein
assay reagent kit (Pierce) according to the supplier's pro-
cedures. Thirty micrograms of total protein lysate were
separated by 10% SDS-PAGE, electroblotted onto nitro-
cellulose membranes (Schleicher & Schuell), and then
probed with anti-phospho-ERK1/2 polyclonal antibodies
or anti-phospho-p38 MAPK polyclonal antibodies (Cell
signaling). Control blots were immunoblotted with anti-
ERK1/2 or anti-p38 MAPK polyclonal antibodies for
whole cell lysates. Immuoblots were then incubated with
HRP-conjugated anti-rabbit antibodies (BD Bioscience).
Finally, the blot was incubated with the Enhanced Chemi-
luminescence System (GE Healthcare) to detect the target
proteins.
Data analysis
All data are presented as the mean ± standard deviation
(SD) obtained from at least three separate experiments
and statistically analyzed by two-tailed, paired t-test. The
statistical significance was defined as *p < 0.05; †p < 0.01;
ψp < 0.005.
Results
Immunomodulatory effects of PGSE on U937 cells 
stimulated by TNF-α
To investigate the immunomodulatory activity of ginseng,
U937 cells were treated with PGSE and followed by TNF-
α stimulation. The gene expression profiles of total cellu-
lar RNA were examined by Affymetrix genechip analysis
and the data were analyzed by using the Affymetrix GCOS
and Genespring GX softwares as described in Methods. To
increase the stringency of the analysis, we combined the
gene lists from the two software analyses. Only the genes
found in both gene lists were reported in this study. Cells
with TNF-α or PGSE treatment only were included, and
the fold induction of cytokines in cells with treatment was
normalized with that of the untreated cells.
Following the sequential treatment of PGSE and TNF-α,
we found that 102 upregulated genes and 64 downregu-
lated genes were repeatedly shown in the gene list of two
analyses (data not shown). To determine the effects of
PGSE on TNF-α signalling pathways, the TNF-α-inducible
cytokines and signalling proteins were grouped and sum-
marized in Table 2. Our results showed that PGSE sup-
pressed the transcription of TNF-α inducible genes
including CXCL-10, NF-κB inhibitor alpha (IκB-α), G
protein-coupled receptor 84, phosphodiesterase 4B,
CXCL-11 and CCL-3 in U937 cells. In contrast, PGSE
enhanced the transcription of IL-8 with TNF-α, but it did
not affect the transcription of CXCL-2, CCL-2, IL-18 recep-
tor, IL-1β and TNF-α-induced protein 3 (TNFIP3). The
genechip results of CXCL-10 and IL-8 were validated by
quantitative RT-PCR and ELISA. Consistently, PGSE
showed inhibition on TNF-α-induced CXCL-10 expres-
sion (Figures 1A and 2A) but augmentation of TNF-α-
induced IL-8 expression (Figures 1B and 2B). By contrast,
there was no significant change of the transcription of
TNFIP3 in TNF-α-treated U937 cells with PGSE treatment
(Figure 1C).
Quantification of ginsenosides by HPLC analysis
Since ginsenosides are major active ingredients in ginseng,
we examined the composition of ginsenosides in PGSE by
HPLC analysis and the results are shown in Figure 3. The
calibration curves of the standard solutions containing
0.5–6.5 μg of each ginsenosides were plotted as the peak
area versus the amount of selected ginsenosides. Individ-
ual ginsenosides from the PGSE were identified and quan-
tified by retention time and peak areas, respectively, as
compared to the commercially available pure standards.
Nine ginsenosides including Rb1, Rb2, Rc, Rd, Re, Rf, Rg1,
Rg3 and Rh1 were identified in the PGSE. The amount,Journal of Translational Medicine 2009, 7:34 http://www.translational-medicine.com/content/7/1/34
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concentration and the percentage of each ginsenoside in 3
mg of PGSE are shown in Table 1.
Differential effects of ginsenosides on TNF-α stimulated-
U937 cells
To investigate whether the CXCL-10 suppressive effect by
3 mg of PGSE was due to a specific ginsenoside, U937
cells were treated with individual ginsenosides using the
amount as listed in Table 1 for 24 hours and followed by
TNF-α stimulation. The level of CXCL-10 transcription
was measured by quantitative RT-PCR. With the exception
of ginsenosides Rb1 and Rb2, our results showed that the
CXCL-10 transcription were significantly inhibited by gin-
senosides including Rd, Re, Rf, Rg1 and Rg3 (p < 0.01), as
well as by Rc and Rh1 (p < 0.05; Figure 4A). However, it is
noted that the extent of the suppressive effect of individ-
ual ginsenosides on CXCL-10 transcription was still less
than that of the PGSE mixture. As ginsenosides accounted
for only 18.8% of PGSE by weight; and thus other constit-
uents present in significant concentrations may modulate
the activity of the ginsenosides.
We then investigated the combinatorial effect of the nine
ginsenosides on TNF-α induced-CXCL-10 transcription.
The nine ginsenosides were standardized to concentra-
tions in the PGSE at 3 mg/ml according to Table 1. More-
over, we included a 10-fold dilution ginsenoside mixture
to examine the dose-dependent effect on CXCL-10 sup-
pression. Interestingly, the suppressive effect of the recon-
stituted mixture of ginsenosides at a dose equivalent to 3
mg/ml of PGSE on TNF-α induced-CXCL-10 transcription
was comparable to the PGSE treatment (Figures 1A and
4B). Moreover, the suppressive effect of the mixture of
ginsenosides occurred in a dose-dependent manner (Fig-
ure 4B). To examine the comparable inhibitory effects of
PGSE and the mixture of ginsenosides, we measured the
percentage change of TNF-α induced-CXCL-10 mRNA
after the pretreatment of 3 mg/ml of PGSE, or the mixture
of ginsenosides that were equivalent to their correspond-
ing amounts in 3 mg/ml of PGSE. Our results showed that
the mixture of ginsenosides gives comparable inhibition
of CXCL-10 transcription to those with PGSE (p < 0.005,
Figure 4C), but the percentage change of CXCL-10 mRNA
between these two treatments was not statistically signifi-
cance (p > 0.1). Hence, our results indicated that the sup-
pressive effect of PGSE on TNF-α induced-CXCL-10
transcription can be due to the combinatorial effect of gin-
senosides.
Inhibition of TNF-α-activated signal transduction 
pathways by PGSE
To investigate the underlying mechanisms of the suppres-
sive effect of the PGSE on CXCL-10 induction, we meas-
ured the activities of MAP kinases, including ERK1/2 and
p38MAPK, by Western analysis. Intense activation of
phospho-ERK1/2 and phospho-p38MAPK was detected
after TNF-α stimulation (lane 1, upper panel, Figure 5A
and 5B). However, the level of ERK1/2 phosphorylation
was decreased with PGSE pretreatment (lanes 2–3, upper
panel, Figure 5A). In contrast, the PGSE did not show
inhibitory effects on TNF-α activated phospho-p38MAPK
activity (lanes 1–3, upper panel, Figure 5B). Interestingly,
we found that PGSE inhibited the basal level of ERK1/2
phosphorylation at 1 or 3 mg/ml (lanes 2 and 3, Figure
5C). Equal loading amount of the proteins in the blot was
shown by staining the immunoblot with anti-ERK1/2
Table 2: Summary of the effect of Panax ginseng extract (PGSE) on TNF-α regulated genes
Mock TNF PGSE+TNF PGSE Gene symbol Description
1.0 53.55 5.61 1.35 CXCL10 Chemokine (C-X-C motif) ligand 10
1.0 13.04 11.03 0.82 TNFAIP3 TNF-α-induced protein 3
1.0 12.40 12.15 1.93 CXCL2 Chemokine (C-X-C motif) ligand 2
1.0 12.28 8.64 1.14 NFKBIA NK-κB inhibitor, alpha
1.0 11.17 9.75 0.88 TNFAIP3 TNF-α-induced protein 3
1.0 7.47 6.04 0.99 IER3 Immediate early response 3
1.0 7.21 2.35 0.86 GPR84 G protein-coupled receptor 84
1.0 7.18 4.90 1.20 NFKBIZ NF-κB inhibitor, zeta
1.0 6.22 4.37 0.62 PDE4B Phosphodiesterase 4B
1.0 6.06 13.38 5.39 IL8 Interleukin 8
1.0 6.05 2.70 0.83 TNFAIP6 TNF-α-induced protein 6
1.0 4.12 1.65 1.10 TNFAIP6 TNF-α-induced protein 6
1.0 3.73 11.23 4.38 IL8 Homo sapiens IL8 C-terminal variant
1.0 3.11 2.23 0.81 CCL3 Chemokine (C-C motif) ligand 3
1.0 2.55 0.64 0.70 CXCL11 Chemokine (C-X-C motif) ligand 11
1.0 2.30 2.51 1.35 CCL2 Chemokine (C-C motif) ligand 2
1.0 1.00 0.50 0.49 IL18R1 Interleukin 18 receptor 1
1.0 0.98 2.12 2.05 IL1B Interleukin 1, beta
1.0 0.92 2.36 1.83 IL1B Interleukin 1, betaJournal of Translational Medicine 2009, 7:34 http://www.translational-medicine.com/content/7/1/34
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antibodies (low panel, Figure 5C). In addition to the
MAPK signalling pathways, we examined the effects of
PGSE on the nuclear translocation of transcription factor
NF-κB in the TNF-α treated cells by Western analysis.
However, the PGSE did not inhibit the nuclear transloca-
tion of p50 and p65 subunits of NF-κB in the TNF-α
treated-cells suggesting that the PGSE targets the ERK1/2
signalling pathways (data not shown).
Discussion
Ginseng is one of the most commonly used herbal medi-
cines in China, Asia and Western countries. Studies have
shown a wide range of beneficial effects of ginseng against
human diseases [25]. The potential therapeutic effects of
ginseng have been attributed to its immunostimulatory,
anti-oxidant and anti-inflammatory activities. In this
study, we used human promonocytic U937 cells to inves-
tigate the modulatory effects of ginseng in cellular
response to TNF-α-mediated inflammation. By using the
genechip approach, we obtained a global gene expression
profile in monocytic cell model following different exper-
imental treatments. Our genechip results showed a potent
suppressive effect of the PGSE on the expression of TNF-
α-inducible genes including CXCL-10. These results have
been validated by using quantitative RT-PCR and ELISA.
Moreover, nine ginsenosides were identified in our gin-
seng extract by using HPLC analysis. Interestingly, other
groups have reported the anti-inflammatory activity of
these ginsenosides. Our results showed that seven out of
nine ginsenosides could significantly inhibit TNF-α-
induced CXCL-10 expression in U937 cells. However, the
suppressive effect of individual ginsenosides on CXCL-10
induction was less than that of the mixture of ginseno-
sides or PGSE alone. Furthermore, we found that the
CXCL-10 suppressive effect correlates with the inactiva-
tion of the ERK1/2 signalling pathways by PGSE.
The immunomodulatory effects of ginseng or ginseno-
sides have been reported in in vivo and in vitro studies. Kim
et al. showed that Panax ginseng enhances the recovery of
natural killer (NK) cell functions in cyclophosphamide-
treated mice, and provides protection against infection
with  Listeria monocytogenes [26]. Ginseng radix extracts
induce production of TNF-α and IFN-γ in murine spleen
cells and peritoneal macrophages via toll-like receptor
(TLR)-4 [5]. Additionally, Ginsenan S-IIA, a component
of acidic polysaccharide of Panax ginseng, is a potent
inducer of IL-8 in human monocytes and THP-1 cells [7].
In contrast, ginseng or ginseng extract have been shown to
have anti-inflammatory effects such as suppressing the
expression of proinflammatory cytokines or mediators.
For instance, ginsan, a polysaccharide extracted from
Panax ginseng, protects mice from lethality induced by Sta-
phylococcus aureus and such effect was associated with sup-
pression of proinflammatory cytokines production
including TNF-α, IL-1β, IL-6, IL-12, IL-18 and IFN-γ [9].
Moreover, 20(S)-Protopanaxatriol, one of the major
metabolites of ginsenosides, inhibits the increase in iNOS
and COX-2 expressions following LPS stimulation
through inactivation of NF-κB [13]. The diverse immuno-
logic effects of ginseng may be due to multiple effects of
the ginsenosides or its other active components. There-
Quantitative RT-PCR analysis of TNF-α regulated genes in  U937 cells after sequential treatment with PGSE and TNF-α Figure 1
Quantitative RT-PCR analysis of TNF-α regulated 
genes in U937 cells after sequential treatment with 
PGSE and TNF-α. U937 cells (1 × 106) were pretreated 
with or without 3 mg/ml PGSE for 24 hours and followed by 
20 units/ml of TNF-α for 2 hours. DNase-treated RNA sam-
ples were reverse transcribed and the levels of mRNA induc-
tion of (A) CXCL-10, (B) IL-8 and (C) TNFAIP3 as well as 
the reference gene 18S rRNA were determined by gene-spe-
cific TaqMan assays as described in Methods. The levels of 
induction were relative to the untreated cells. Values repre-
sent the average ± SD of three independent experiments and 
statistically analyzed by two tailed, paired t-test. *: p < 0.05. 
PGSE, 70% ethanol-water extracts of ginseng; CXCL-10, 
interferon gamma-inducible protein-10; IL-8, interleukin-8; 
TNFAIP3, TNF-α-induced protein 3.Journal of Translational Medicine 2009, 7:34 http://www.translational-medicine.com/content/7/1/34
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fore, comprehensive studies of ginseng and its constitu-
ents are still needed to provide detailed understanding of
their actions in humans.
Since our study is focused on immunomodulation, only
the list of cytokines or cytokine-regulated genes is
reported in Table 2. Here, the PGSE can cause a potent
inhibition on the transcription of TNF-α inducible genes
including CXCL-10, G protein-coupled receptor 84, TNF-
α induced-protein 6, IκB-alpha, IκB-zeta and phosphodi-
esterase 4B (Table 2). Interestingly, those genes inhibited
by PGSE have been shown to be expressed in TNF-α medi-
ated-inflammatory diseases [15,27-29]. Therefore, it is
plausible that ginseng down regulates TNF-α mediated
inflammation through suppressing the production of
inflammatory mediators in monocytes or macrophages.
However, it seems that this PGSE preparation did not con-
tain potent cytokine inducing factors. As previous reports
showed that the immunostimulating components such as
polysaccharides of ginseng extracts come from the ethanol
insoluble fraction [7,30,31], this component appears to
have been excluded or its biological activity was attenu-
ated by constituents in the extract we studied.
CXCL-10 is an important chemokine downstream of TNF-
α signalling pathways and a well-documented mediator
of inflammation. CXCL-10 initiates its biological func-
tions through binding to its high affinity receptor CXCR-
3 leading to recruitment of the activated effector lym-
phocytes including CD4+ and CD8+ T cells as well as NK
cells to the site of infection or injury [32]. Similar to TNF-
α, the uncontrolled production of CXCL-10 also is associ-
ated with the pathogenesis of acute and chronic inflam-
matory diseases including intrahepatic inflammation
during chronic HCV infection, atherosclerosis, inflamma-
tory bowel disease, and multiple sclerosis as well as tum-
origenesis and metastasis [33-37]. In our study, the PGSE
Quantification of CXCL-10 and IL-8 in culture supernatant of  U937 cells by ELISA Figure 2
Quantification of CXCL-10 and IL-8 in culture super-
natant of U937 cells by ELISA. U937 cells were pre-
treated with or without 3 mg/ml PGSE for 24 hours prior to 
20 units/ml TNF-α stimulation for 16 hours. After treatment, 
the level of CXCL-10 in culture supernatants was measured 
by specific ELISA kit according to the supplier's procedures. 
Values represent the average ± SD of three independent 
experiments and statistically analyzed by two tailed, paired t-
test. *: p < 0.05. PGSE, 70% ethanol-water extracts of gin-
seng; CXCL-10, interferon gamma-inducible protein-10; IL-8, 
interleukin-8.
High performance liquid chromatography analysis of PGSE Figure 3
High performance liquid chromatography analysis of 
PGSE. The separation was done by using a reversed-phase 
column Lichrospher 100 C18 reversed-phase and the detec-
tion wavelength was set at 203 nm for all ginsenosides. The 
gradient program consisted of two solvents (A) water and 
(B) acetonitrile at a flow of 1 mL/min as follows: 0–6 min, 21–
22% B; 6–7 min, 22–23% B; 7–25 min, 23–24% B; 25–30 min, 
24–30% B; 30–40 min, 30–32% B; 40–45 min, 32–50% B; 45–
60 min, 50–65% B; 60–61 min, 65–100% B; and 61–65 min, 
back to 21% B before the next injection for analysis. Twenty 
micrograms of PGSE was injected each time.Journal of Translational Medicine 2009, 7:34 http://www.translational-medicine.com/content/7/1/34
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or chemically defined mixture of its constituent ginseno-
sides showed potent inhibitory effects on TNF-α-stimu-
lated CXCL-10 expression (Figure 4C) suggesting a
specific anti-inflammatory property of ginseng.
Ginsenosides belong to a family of steroidal saponins that
are believed to be responsible for the pharmacological
effects of ginseng. About 30 different ginsenosides have
been isolated and identified from Panax ginseng. The two
Suppressive effects of ginsenosides on U937 cells stimulated  with TNF-α Figure 4
Suppressive effects of ginsenosides on U937 cells 
stimulated with TNF-α. (A) Nine ginsenosides were 
standardized to concentrations in the PGSE at 3 mg/ml 
according to Table 1. U937 cells were treated with ginseno-
sides for 24 hours following with 20 units/ml TNF-α stimula-
tion for 2 hours, and the transcription of CXCL-10 was 
measured by quantitative RT-PCR as described in Methods. 
(B) Ginsenosides including Rb1, Rb2, Rc, Rd, Re, Rf, Rg1, Rg3 
and Rh1 were pooled together to investigate the combinato-
rial effect of the nine ginsenosides on CXCL-10 transcription 
following TNF-α stimulation by using quantitative RT-PCR. 
(C) Comparable inhibitory effects of the ginseng extract 
(PGSE) and the mixture of individual ginsenosides on CXCL-
10 transcription. U937 cells were treated with 3 mg/ml of 
PGSE or the mixture of GS (that is equivalent to 3 mg/ml of 
PGSE) for 24 hours following with 20 units/ml of TNF-α 
stimulation for another 2 hours. The transcription of CXCL-
10 was measured by quantitative RT-PCR as described in 
Methods. Values represent the average ± SD of three inde-
pendent experiments and statistically analyzed by two tailed, 
paired t-test. ψ: p < 0.005; †: p < 0.01; *: p < 0.05. GS, ginse-
nosides; PGSE, 70% ethanol-water extracts of ginseng.
Inhibition of MAP kinases activation after PGSE treatment Figure 5
Inhibition of MAP kinases activation after PGSE 
treatment. U937 cells were treated with PGSE (1 or 3 mg/
ml) for 24 hours followed by 20 units/ml TNF-α stimulation 
for 2 hours. Whole cell protein lysate was analyzed by West-
ern analysis using (A) anti-phospho ERK1/2 antibodies; and 
(B) anti-phospho p38MAPK antibodies as described in Meth-
ods. (C) Cell lysate with PGSE treatment only was analyzed 
by anti-phospho ERK1/2 antibodies. Equal amount of protein 
loading in the blot was shown by staining the immunoblot 
with anti-ERK1/2 or anti-p38MAPK antibodies. PGSE, 70% 
ethanol-water extracts of ginseng.Journal of Translational Medicine 2009, 7:34 http://www.translational-medicine.com/content/7/1/34
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major groups of ginsenosides are panaxadiol and panaxa-
triol. The panaxadiol group contains Rb1, Rb2, Rc, Rd and
Rh2 whereas the panaxatriol group contains Re, Rf, Rg1,
Rg2,Rg3 and Rh1. Previous studies have shown different
properties of ginsenosides among each other, and differ-
ential effects of ginsenosides panaxadiol and panaxatriols
have been found in inflammatory diseases [38]. Here, we
found that both of the panaxadiol and panaxatriol groups
of ginsenosides showed similar inhibitory effects on TNF-
α-induced CXCL-10 production. Additionally, the inhibi-
tory effects could be due to complementary or collective
effect of ginsenosides mixtures instead of a single ginseno-
side. Another possible explanation is stereoisomerism of
natural and synthetic compounds since the source of gin-
senosides is different from the ginseng extract. Similar
phenomenon has been reported by another group
recently [39].
Following the activation of TNF-α signalling pathways,
the downstream MAPK cascades and transcription factors,
NF-κB and AP-1, are activated to induce gene transcrip-
tion. Previous studies have shown that NF-κB and/or
MAPK signalling cascades play critical roles in acute and
chronic inflammatory diseases. Here our result showed
that the PGSE inhibited the basal level of ERK1/2 phos-
phorylation at 1 or 3 mg/ml (Figure 5C). This observation
is in agreement with the effect of PD98059, a known
inhibitor of ERK1/2, on the suppression of TNF-α-
induced CXCL-10 transcription (not shown). In contrast,
the PGSE did not show any effect on TNF-α-induced acti-
vation of p38MAPK and NF-κB. These results suggest that
PGSE inhibited CXCL-10 expression by perturbing MAPK
signalling cascades.
Conclusion
In conclusion, the results of this study provide evidence
that ginseng can suppress TNF-α-inducible cytokines and
signalling proteins in promonocytic cells. The suppressive
effect of the reconstituted mixture of individual ginseno-
sides on TNF-α induced-CXCL-10 transcription was com-
parable to that of the PGSE treatment. Moreover, ginseng
down regulated CXCL-10 expression by suppressing TNF-
α-induced ERK1/2 activation. Thus, ginseng may exert its
anti-inflammatory properties by targeting at different lev-
els of the TNF-α signalling pathways. Further studies will
be needed to examine the potential beneficial effects of
ginsenosides in the management of acute and chronic
inflammatory diseases in humans.
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